AstraZeneca's Brilinta now available

Drug approved for treating acute coronary syndrome

WILMINGTON, Del. — A new drug made by AstraZeneca is available in pharmacies following its regulatory approval in July, the company said Monday.

AstraZeneca announced the availability of the anti-platelet drug Brilinta (ticagrelor) for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.

The Food and Drug Administration approved Brilinta on July 20. AstraZeneca said the drug has been shown to reduce the rates of cardiovascular death, heart attacks and stroke, compared with other drugs on the market.

Login or Register to post a comment.